Apple's workaround for the Masimo patent dispute could hurt MASI stock. But the solution—shifting blood oxygen calculations to the iPhone—is not a guaranteed win. With a reported 92% accuracy, it may struggle to impress the FDA and customers. If it fails, Masimo's stock could rebound. #Apple #Masimo #PatentLaw
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.